MASTL/Aurora A-IN-1

MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases with IC50 values of 0.56 μM and 0.16 μM, respectively. MASTL/Aurora A-IN-1 has broad-spectrum anticancer activity and has potent anticancer activity against SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) cell lines in NCI-60 cancer cell lines with GI50 values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM, respectively. MASTL/Aurora A-IN-1 inhibits Aurora A and MASTL kinases, inducing cell cycle G2/M arrest, thereby inhibiting cancer cell proliferation. MASTL/Aurora A-IN-1 can be used in cancer research, especially for tumors with dysregulated mitosis[1].

Product Specifications

CAS Number

[321945-24-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Aurora Kinase; MASTL; Ser/Thr Protease

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.47

Solubility

DMSO : 116.67 mg/mL (ultrasonic)

Smiles

O=C(NC1=C(C#N)C(CCCC2)=C2S1)CCC3=CC=CC=C3

Molecular Formula

C18H18N2OS

Molecular Weight

310.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Abdel-Rahman SA, Nada H, Gabr MT. First-in-class dual inhibitors of MASTL and Aurora A kinase: Discovery of selective cyclohexa[b]thiophenes with potent anticancer activity. Eur J Med Chem. 2025 May 8;293:117729.